Insider · CIK 0002063117
Michael C. Quirk
officer
Files at SAGE (Sage Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Common Stock | -24,999 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Common Stock | -7,962 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -36,000 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,000 | - | - | 0 | Jul 31, 2025 |
| Jun 24, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -113 | $9.22 | $1,042 | 30,461 | Jun 26, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +933 | $0.00 | $0 | 30,041 | Apr 11, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -312 | $6.91 | $2,156 | 29,729 | Apr 11, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +1,269 | $0.00 | $0 | 30,998 | Apr 11, 2025 |
| Apr 10, 2025 | SAGE Sage Therapeutics, Inc. | FTax withholding Common Stock | -424 | $6.91 | $2,930 | 30,574 | Apr 11, 2025 |
| Apr 1, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 29,108 | Apr 2, 2025 |
| Apr 1, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Sderivative | +4,000 | $0.00 | $0 | 4,000 | Apr 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.